JNJ-80948543 is named as an intervention in 3 current clinical trials in our China, UK and USA registers. None are recruiting at the moment. All registered phases are Phase 1. The lead sponsor is Janssen Research & Development, LLC. The most-studied condition is Lymphoma, Non-Hodgkin.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin
|
Phase 1 | By invitation | Janssen Research & Development, LLC | UK, China |
|
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT05424822 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
|
Phase 1 | Active, closed | Janssen Research & Development, LLC | USA, China |
|
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
NCT06660563 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin
|
Phase 1 | Active, closed | Janssen Research & Development, LLC | UK, China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Janssen Research & Development, LLC | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 0 |
| Clinical trials in UK | 2 | 0 |
| Clinical trials in USA | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China, UK and USA registers name JNJ-80948543 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Janssen Research & Development, LLC. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how JNJ-80948543 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how JNJ-80948543 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists JNJ-80948543 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.